Glioblastoma Multiforme
Conditions
Brief summary
A study of single-agent birabresib (MK-8628) (formerly known as OTX015) in recurrent GBM after standard front-line therapy failure. The first phase of the study (dose escalation) will determine the maximum tolerated dose (MTD). MTD assessment will be based using dose-limiting toxicities (DLTs) observed during the first 28 days of treatment. The second phase of the study (expansion cohort) will assess efficacy as measured by the progression-free survival rate at 6 months (PFS-6) as determined by an independent central review committee.
Interventions
DRUGBirabresib
Administered orally in a fasted state once daily.
Sponsors
Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Has signed informed consent obtained prior to initiation of any study-specific procedures and treatment. Participants registered for this trial must be treated and followed at the participating centers * Has a histologically confirmed diagnosis of de novo glioblastoma multiforme (World Health Organization grade IV astrocytoma) with unequivocal tumor recurrence by magnetic resonance imaging (MRI) scan (performed on a stable steroid dosage received for at least 5 days) following front-line treatment with surgical resection, cranial radiotherapy and temozolomid. Participants who do not undergo surgical resection as part of front-line therapy due to anatomical location based on neurosurgeon's assessment will be permitted if a confirmatory tumor biopsy was performed * Has at least one measurable and/or non-measurable lesion as per Response Assessment in Neuro-Oncology (RANO) criteria (Wen et al., 2010) * Is at least 18 years old * Has a life expectancy \>3 months; * Has a Karnofsky performance status (KPS) ≥70% * Has adequate bone marrow reserve, renal and liver function as demonstrated by the following: absolute neutrophil count ≥1.5 x109/L; platelet count ≥150 x109/L; hemoglobin ≥10 g/dL; creatinine 2 x the upper limit of normal (ULN) or calculated creatinine clearance ≥30 mL/min (Cockroft and Gault formula or Modification of Diet in Renal Disease \[MDRD\] formula for participants aged \>65 years); alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3 x ULN, and total bilirubin ≤ULN * Has an interval of ≥2 weeks since surgical resection, ≥4 weeks since chemotherapy (≥6 weeks for nitrosoureas), and ≥12 weeks since radiotherapy completion when starting study treatment. Participants with recent tumor resection must have an MRI within 48 hours post-surgery * Has archived tumor pathology specimen (paraffin-embedded or frozen block)
Exclusion criteria
* Has had prior antineoplastic treatment for recurrent disease including vascular endothelial growth factor (VEGF)/vascular endothelial growth factor receptor (VEGFR) inhibitors and cytotoxic agents * Is unable to undergo MRI because of non-compatible devices * Is unable to swallow oral medications or presence of a gastrointestinal disorder (e.g. malabsorption, resection) deemed to jeopardize intestinal absorption * Has persistent grade \>1 clinically significant toxicities related to prior antineoplastic therapies * Has a history of prior or concomitant malignancies within 5 years of study entry (other than excised non-melanoma skin cancer or cured in situ cervical carcinoma). Male participants with concurrent controlled hormone dependent prostate cancer are allowed * Has other serious illness or medical conditions which in the investigator's opinion could hamper understanding of the study by the participant, the participant's compliance to study treatment, participant's safety, or interpretation of study results. These include (but are not restricted to) existence of significant neurologic or psychiatric disorders impairing the ability to obtain consent, uncontrolled infection and known HIV positivity * Is taking enzyme-inducing antiepileptic drug (EIAED) * Is taking strong CYP3A4 interacting drugs * Is participating in another clinical trial or treatment with any investigational drug within 4 weeks prior to first study treatment administration, or 5 half-lives of previously administered drugs, whichever is longer * Is pregnant or breast feeding * Is not using effective contraception while on study treatment if a participant of child-bearing potential
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free Survival (PFS) at 6 Months | Month 6 | Progression-free survival was the time from the start of study treatment to the date of clinical or radiographic evidence of progressive disease according to Response Assessment in Neuro-Oncology (RANO) 2010 criteria or death. Progression, as assessed by RANO 2010, was defined as a ≥25% increase in sum of the products of perpendicular diameters of enhancing lesions; any new lesion; or clinical deterioration. PFS at 6 months was measured as the percentage of participants who were alive and progression-free at Month 6. PFS at 6 months was calculated for all participants who were actively enrolled in the study at the 6-month time point. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Duration of Response (DOR) | Up to 6 Months | DOR was the time from the first documented CR (complete disappearance of all enhancing measurable and non-measurable disease sustained for at least 4 weeks; no new lesions; no corticosteroids; and stable or improved clinically)or PR (≥50% decrease compared with baseline in the sum of products of perpendicular diameters of all measurable enhancing lesions sustained for at least 4 weeks; no new lesions; stable or reduced corticosteroid dose; and stable or improved clinically), as assessed by RANO 2010, until documentation of disease progression, or the date of the last tumor assessment (if there was no documented progression), or the last tumor assessment before the start of further antitumor therapy. DOR was calculated for all participants who experienced a CR or PR. |
| Overall Survival (OS) | Up to 6 Months | OS was the time from the start of study treatment to the date of death. Participants were to be censored at their last contact if they were still alive at the cut-off date. OS was calculated for all participants who did not discontinue from the study due to disease progression. |
| Progression-free Survival | Up to 6 Months | Progression-free survival was the time from the start of study treatment to the date of clinical or radiographic evidence of progressive disease according to RANO 2010 criteria or death. Progression, as assessed by RANO 2010, was defined as a ≥25% increase in sum of the products of perpendicular diameters of enhancing lesions; any new lesion; or clinical deterioration. PFS was measured as the number of participants who were alive and progression-free for up to 6 months. |
| Time to Maximum Concentration (Tmax) of MK-8628 | Day 1: Predose and 0.25, 1, 2, 3, 7, and 8 hours postdose | Blood samples were obtained at specified time points for the PK analysis of Tmax of MK-8628. MK-8628 concentrations were analyzed using ultra-performance liquid chromatography coupled with a tandem mass spectrometry and Tmax was calculated using the nonlinear mixed-effects modelling software program Monolix version 4.3.2s. The Tmax of MK-8628 after oral administration is presented. |
| Number of Participants Who Experienced at Least One Adverse Event (AE) | Up to 6 Months | An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product/protocol-specified procedure, whether or not considered related to the medicinal product/protocol-specified procedure. Any worsening of a preexisting condition temporally associated with the use of the product was also an AE. The number of participants who experienced at least one AE is presented. |
| Number of Participants Who Experienced at Least One Toxicity Grade 3-5 AE | Up to 6 Months | An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product/protocol-specified procedure. Any worsening of a preexisting condition temporally associated with the use of the product was also an AE. The number of participants who experienced ≥1 Grade 3-5 AE per National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE) Version 4.03 criteria is presented. Grade 3 was classified as severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; or limiting self-care; Grade 4 was classified as potentially life-threatening or disabling; and Grade 5 was an AE resulting in death. |
| Number of Participants Who Discontinued Study Treatment Due to an AE | Up to 6 Months | The number of participants who discontinued study treatment due to an AE is presented. |
| Objective Response Rate (ORR) | Up to 6 Months | ORR was defined as the number of participants in the analysis population who experienced a Complete Response (CR: complete disappearance of all enhancing measurable and non-measurable disease sustained for at least 4 weeks; no new lesions; no corticosteroids; and stable or improved clinically) or a Partial Response (PR: ≥50% decrease compared with baseline in the sum of products of perpendicular diameters of all measurable enhancing lesions sustained for at least 4 weeks; no new lesions; stable or reduced corticosteroid dose; and stable or improved clinically) and was assessed using RANO 2010. |
| Observed Maximum Concentration (Cmax) of MK-8628 | Day 1: Predose and 0.25, 1, 2, 3, 7, and 8 hours postdose | Blood samples were obtained at specified time points for the pharmacokinetic (PK) analysis of Cmax of MK-8628. MK-8628 concentrations were analyzed using ultra-performance liquid chromatography coupled with a tandem mass spectrometry and Cmax was calculated using the nonlinear mixed-effects modelling software program Monolix version 4.3.2s. The Cmax of MK-8628 after oral administration is presented. |
| Apparent Terminal Half-Life (t1/2) of MK-8628 | Day 1: Predose and 0.25, 1, 2, 3, 7, and 8 hours | Blood samples were obtained at specified time points for the PK analysis of t1/2 of MK-8628. MK-8628 concentrations were analyzed using ultra-performance liquid chromatography coupled with a tandem mass spectrometry and t1/2 was calculated using the nonlinear mixed-effects modelling software program Monolix version 4.3.2s. The t1/2 of MK-8628 after oral administration is presented. |
| Apparent Total Body Clearance (Cl/F) of MK-8628 | Day 1: Predose and 0.25, 1, 2, 3, 7, and 8 hours | Blood samples were obtained at specified time points for the PK analysis of Cl/F of MK-8628. MK-8628 concentrations were analyzed using ultra-performance liquid chromatography coupled with a tandem mass spectrometry and Cl/F was calculated using the nonlinear mixed-effects modelling software program Monolix version 4.3.2s. The Cl/F of MK-8628 after oral administration is presented. |
| Apparent Volume of Distribution During the Terminal Phase (Vz/F) of MK-8628 | Day 1: Predose and 0.25, 1, 2, 3, 7, and 8 hours | Blood samples were obtained at specified time points for the PK analysis of Vz/F of MK-8628. MK-8628 concentrations were analyzed using ultra-performance liquid chromatography coupled with a tandem mass spectrometry and Vz/F was calculated using the nonlinear mixed-effects modelling software program Monolix version 4.3.2s. The Vz/F of MK-8628 after oral administration is presented. |
| Observed Minimum Concentration (Cmin) of MK-8628 | Predose on Days 29 and 57 | Blood samples were obtained at specified time points for the PK analysis of Cmin of MK-8628. MK-8628 concentrations were analyzed using ultra-performance liquid chromatography coupled with a tandem mass spectrometry. A single Cmin value for MK-8628 was estimated using dose and steady-state predose concentrations of MK-8628 on Days 29 and 57. The Cmin of MK-8628 after oral administration is presented. |
| Area Under the Concentration-time Curve of MK-8628 From Time 0 to Infinity (AUC 0-∞) | Day 1: Predose and 0.25, 1, 2, 3, 7, and 8 hours | Blood samples were obtained at specified time points for the PK analysis of AUC 0-∞ of MK-8628. MK-8628 concentrations were analyzed using ultra-performance liquid chromatography coupled with a tandem mass spectrometry. The AUC 0-∞ was estimated indirectly using the dose and CL/F values. The AUC 0-∞ of MK-8628 after oral administration is presented. |
| Number of Participants Who Experienced a Dose Limiting Toxicity (DLT) During Cycle 1 | Up to Cycle 1 (Up to 28 days) | A DLT was defined as any of the following toxicities that were considered by the investigator to be related to MK-8628: Hematologic toxicity: Grade 4 hematologic toxicity or febrile neutropenia, Grade 3 neutropenia with infection, Grade 3 thrombocytopenia with bleeding or lasting \>7 days; Non-hematologic toxicity: Grade 3 or 4 non-hematologic toxicity (regardless of duration) unless it was not optimally managed with supportive care, Grade 3 or 4 laboratory abnormality lasting \>7 days, or intolerable Grade 2 non-hematologic toxicity resulting in study treatment discontinuation or delay \>7 days with or without dose reduction. |
Participant flow
Recruitment details
Participants had a confirmed diagnosis of de novo glioblastoma multiforme (World Health Organization grade IV astrocytoma) with tumor recurrence following standard front-line treatment with surgery, cranial radiotherapy and temozolomide. Other inclusion and exclusion criteria applied.
Participants by arm
| Arm | Count |
|---|---|
| MK-8628 80 mg Participants received 80 mg of oral MK-8628 administered once daily (in a fasted state) every day in a 28-day cycle for up to 6 cycles. | 6 |
| MK-8628 120 mg Participants received 120 mg of oral MK-8628 administered once daily (in a fasted state) every day in a 28-day cycle for up to 6 cycles. | 4 |
| MK-8628 160 mg Participants received 160 mg of oral MK-8628 administered once daily (in a fasted state) every day in a 28-day cycle for up to 6 cycles. | 2 |
| Total | 12 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 |
|---|---|---|---|---|
| Overall Study | Disease Progression | 6 | 4 | 2 |
Baseline characteristics
| Characteristic | MK-8628 80 mg | MK-8628 120 mg | MK-8628 160 mg | Total |
|---|---|---|---|---|
| Age, Continuous | 49.7 Years STANDARD_DEVIATION 14.2 | 55.8 Years STANDARD_DEVIATION 11.2 | 54.5 Years STANDARD_DEVIATION 21.9 | 52.5 Years STANDARD_DEVIATION 13.3 |
| Race and Ethnicity Not Collected | — | — | — | 0 Participants |
| Sex: Female, Male Female | 2 Participants | 0 Participants | 0 Participants | 2 Participants |
| Sex: Female, Male Male | 4 Participants | 4 Participants | 2 Participants | 10 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 6 | 0 / 4 | 0 / 2 |
| other Total, other adverse events | 6 / 6 | 4 / 4 | 2 / 2 |
| serious Total, serious adverse events | 1 / 6 | 0 / 4 | 2 / 2 |
Outcome results
Primary
Progression-free Survival (PFS) at 6 Months
Progression-free survival was the time from the start of study treatment to the date of clinical or radiographic evidence of progressive disease according to Response Assessment in Neuro-Oncology (RANO) 2010 criteria or death. Progression, as assessed by RANO 2010, was defined as a ≥25% increase in sum of the products of perpendicular diameters of enhancing lesions; any new lesion; or clinical deterioration. PFS at 6 months was measured as the percentage of participants who were alive and progression-free at Month 6. PFS at 6 months was calculated for all participants who were actively enrolled in the study at the 6-month time point.
Time frame: Month 6
Population: All participants who received at least 2 complete cycles (8 weeks) of treatment and had a baseline assessment and 1 on-study magnetic resonance imaging (MRI). Since no participants reached the 6-month time point in the study, PFS at 6 months could not be calculated.
Secondary
Apparent Terminal Half-Life (t1/2) of MK-8628
Blood samples were obtained at specified time points for the PK analysis of t1/2 of MK-8628. MK-8628 concentrations were analyzed using ultra-performance liquid chromatography coupled with a tandem mass spectrometry and t1/2 was calculated using the nonlinear mixed-effects modelling software program Monolix version 4.3.2s. The t1/2 of MK-8628 after oral administration is presented.
Time frame: Day 1: Predose and 0.25, 1, 2, 3, 7, and 8 hours
Population: All participants who received MK-8628 and had blood samples drawn for PK analyses.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| MK-8628 80 mg | Apparent Terminal Half-Life (t1/2) of MK-8628 | 3.78 hours | Standard Deviation 0.366 |
| MK-8628 120 mg | Apparent Terminal Half-Life (t1/2) of MK-8628 | 3.74 hours | Standard Deviation 0.431 |
| MK-8628 160 mg | Apparent Terminal Half-Life (t1/2) of MK-8628 | 3.50 hours | — |
Secondary
Apparent Total Body Clearance (Cl/F) of MK-8628
Blood samples were obtained at specified time points for the PK analysis of Cl/F of MK-8628. MK-8628 concentrations were analyzed using ultra-performance liquid chromatography coupled with a tandem mass spectrometry and Cl/F was calculated using the nonlinear mixed-effects modelling software program Monolix version 4.3.2s. The Cl/F of MK-8628 after oral administration is presented.
Time frame: Day 1: Predose and 0.25, 1, 2, 3, 7, and 8 hours
Population: All participants who received MK-8628 and had blood samples drawn for PK analyses.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| MK-8628 80 mg | Apparent Total Body Clearance (Cl/F) of MK-8628 | 10.4 Liters/hour | Standard Deviation 2.19 |
| MK-8628 120 mg | Apparent Total Body Clearance (Cl/F) of MK-8628 | 13.0 Liters/hour | Standard Deviation 4.03 |
| MK-8628 160 mg | Apparent Total Body Clearance (Cl/F) of MK-8628 | 7.75 Liters/hour | — |
Secondary
Apparent Volume of Distribution During the Terminal Phase (Vz/F) of MK-8628
Blood samples were obtained at specified time points for the PK analysis of Vz/F of MK-8628. MK-8628 concentrations were analyzed using ultra-performance liquid chromatography coupled with a tandem mass spectrometry and Vz/F was calculated using the nonlinear mixed-effects modelling software program Monolix version 4.3.2s. The Vz/F of MK-8628 after oral administration is presented.
Time frame: Day 1: Predose and 0.25, 1, 2, 3, 7, and 8 hours
Population: All participants who received MK-8628 and had blood samples drawn for PK analyses.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| MK-8628 80 mg | Apparent Volume of Distribution During the Terminal Phase (Vz/F) of MK-8628 | 56.3 Liters | Standard Deviation 9.73 |
| MK-8628 120 mg | Apparent Volume of Distribution During the Terminal Phase (Vz/F) of MK-8628 | 70.3 Liters | Standard Deviation 24.1 |
| MK-8628 160 mg | Apparent Volume of Distribution During the Terminal Phase (Vz/F) of MK-8628 | 39.3 Liters | — |
Secondary
Area Under the Concentration-time Curve of MK-8628 From Time 0 to Infinity (AUC 0-∞)
Blood samples were obtained at specified time points for the PK analysis of AUC 0-∞ of MK-8628. MK-8628 concentrations were analyzed using ultra-performance liquid chromatography coupled with a tandem mass spectrometry. The AUC 0-∞ was estimated indirectly using the dose and CL/F values. The AUC 0-∞ of MK-8628 after oral administration is presented.
Time frame: Day 1: Predose and 0.25, 1, 2, 3, 7, and 8 hours
Population: All participants who received MK-8628 and had blood samples drawn for PK analyses.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| MK-8628 80 mg | Area Under the Concentration-time Curve of MK-8628 From Time 0 to Infinity (AUC 0-∞) | 8028 μg•hours/Liter | Standard Deviation 2083 |
| MK-8628 120 mg | Area Under the Concentration-time Curve of MK-8628 From Time 0 to Infinity (AUC 0-∞) | 10200 μg•hours/Liter | Standard Deviation 4312 |
| MK-8628 160 mg | Area Under the Concentration-time Curve of MK-8628 From Time 0 to Infinity (AUC 0-∞) | 20700 μg•hours/Liter | — |
Secondary
Duration of Response (DOR)
DOR was the time from the first documented CR (complete disappearance of all enhancing measurable and non-measurable disease sustained for at least 4 weeks; no new lesions; no corticosteroids; and stable or improved clinically)or PR (≥50% decrease compared with baseline in the sum of products of perpendicular diameters of all measurable enhancing lesions sustained for at least 4 weeks; no new lesions; stable or reduced corticosteroid dose; and stable or improved clinically), as assessed by RANO 2010, until documentation of disease progression, or the date of the last tumor assessment (if there was no documented progression), or the last tumor assessment before the start of further antitumor therapy. DOR was calculated for all participants who experienced a CR or PR.
Time frame: Up to 6 Months
Population: All participants who received at least 2 complete cycles (8 weeks) of treatment and had a baseline assessment and 1 on-study MRI or had discontinued early due to disease progression. Since no participants experienced a CR or PR, DOR could not be calculated.
Secondary
Number of Participants Who Discontinued Study Treatment Due to an AE
The number of participants who discontinued study treatment due to an AE is presented.
Time frame: Up to 6 Months
Population: All participants who received at least one dose of study treatment.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| MK-8628 80 mg | Number of Participants Who Discontinued Study Treatment Due to an AE | 0 Participants |
| MK-8628 120 mg | Number of Participants Who Discontinued Study Treatment Due to an AE | 0 Participants |
| MK-8628 160 mg | Number of Participants Who Discontinued Study Treatment Due to an AE | 0 Participants |
Secondary
Number of Participants Who Experienced a Dose Limiting Toxicity (DLT) During Cycle 1
A DLT was defined as any of the following toxicities that were considered by the investigator to be related to MK-8628: Hematologic toxicity: Grade 4 hematologic toxicity or febrile neutropenia, Grade 3 neutropenia with infection, Grade 3 thrombocytopenia with bleeding or lasting \>7 days; Non-hematologic toxicity: Grade 3 or 4 non-hematologic toxicity (regardless of duration) unless it was not optimally managed with supportive care, Grade 3 or 4 laboratory abnormality lasting \>7 days, or intolerable Grade 2 non-hematologic toxicity resulting in study treatment discontinuation or delay \>7 days with or without dose reduction.
Time frame: Up to Cycle 1 (Up to 28 days)
Population: All participants who received at least 21 days of the planned dose of study drug during the first 28-day cycle or experienced a DLT.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| MK-8628 80 mg | Number of Participants Who Experienced a Dose Limiting Toxicity (DLT) During Cycle 1 | 1 Participants |
| MK-8628 120 mg | Number of Participants Who Experienced a Dose Limiting Toxicity (DLT) During Cycle 1 | 0 Participants |
| MK-8628 160 mg | Number of Participants Who Experienced a Dose Limiting Toxicity (DLT) During Cycle 1 | 2 Participants |
Secondary
Number of Participants Who Experienced at Least One Adverse Event (AE)
An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product/protocol-specified procedure, whether or not considered related to the medicinal product/protocol-specified procedure. Any worsening of a preexisting condition temporally associated with the use of the product was also an AE. The number of participants who experienced at least one AE is presented.
Time frame: Up to 6 Months
Population: All participants who received at least one dose of study treatment.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| MK-8628 80 mg | Number of Participants Who Experienced at Least One Adverse Event (AE) | 6 Participants |
| MK-8628 120 mg | Number of Participants Who Experienced at Least One Adverse Event (AE) | 4 Participants |
| MK-8628 160 mg | Number of Participants Who Experienced at Least One Adverse Event (AE) | 2 Participants |
Secondary
Number of Participants Who Experienced at Least One Toxicity Grade 3-5 AE
An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product/protocol-specified procedure. Any worsening of a preexisting condition temporally associated with the use of the product was also an AE. The number of participants who experienced ≥1 Grade 3-5 AE per National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE) Version 4.03 criteria is presented. Grade 3 was classified as severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; or limiting self-care; Grade 4 was classified as potentially life-threatening or disabling; and Grade 5 was an AE resulting in death.
Time frame: Up to 6 Months
Population: All participants who received at least one dose of study treatment.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| MK-8628 80 mg | Number of Participants Who Experienced at Least One Toxicity Grade 3-5 AE | 3 Participants |
| MK-8628 120 mg | Number of Participants Who Experienced at Least One Toxicity Grade 3-5 AE | 1 Participants |
| MK-8628 160 mg | Number of Participants Who Experienced at Least One Toxicity Grade 3-5 AE | 2 Participants |
Secondary
Objective Response Rate (ORR)
ORR was defined as the number of participants in the analysis population who experienced a Complete Response (CR: complete disappearance of all enhancing measurable and non-measurable disease sustained for at least 4 weeks; no new lesions; no corticosteroids; and stable or improved clinically) or a Partial Response (PR: ≥50% decrease compared with baseline in the sum of products of perpendicular diameters of all measurable enhancing lesions sustained for at least 4 weeks; no new lesions; stable or reduced corticosteroid dose; and stable or improved clinically) and was assessed using RANO 2010.
Time frame: Up to 6 Months
Population: All participants who received at least 2 complete cycles (8 weeks) of treatment and had a baseline assessment and 1 on-study MRI or had discontinued early due to disease progression.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| MK-8628 80 mg | Objective Response Rate (ORR) | 0 Participants |
| MK-8628 120 mg | Objective Response Rate (ORR) | 0 Participants |
| MK-8628 160 mg | Objective Response Rate (ORR) | 0 Participants |
Secondary
Observed Maximum Concentration (Cmax) of MK-8628
Blood samples were obtained at specified time points for the pharmacokinetic (PK) analysis of Cmax of MK-8628. MK-8628 concentrations were analyzed using ultra-performance liquid chromatography coupled with a tandem mass spectrometry and Cmax was calculated using the nonlinear mixed-effects modelling software program Monolix version 4.3.2s. The Cmax of MK-8628 after oral administration is presented.
Time frame: Day 1: Predose and 0.25, 1, 2, 3, 7, and 8 hours postdose
Population: All participants who received MK-8628 and had blood samples drawn for PK analyses.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| MK-8628 80 mg | Observed Maximum Concentration (Cmax) of MK-8628 | 1022 μg/Liter | Standard Deviation 377 |
| MK-8628 120 mg | Observed Maximum Concentration (Cmax) of MK-8628 | 1138 μg/Liter | Standard Deviation 527 |
| MK-8628 160 mg | Observed Maximum Concentration (Cmax) of MK-8628 | 2725 μg/Liter | — |
Secondary
Observed Minimum Concentration (Cmin) of MK-8628
Blood samples were obtained at specified time points for the PK analysis of Cmin of MK-8628. MK-8628 concentrations were analyzed using ultra-performance liquid chromatography coupled with a tandem mass spectrometry. A single Cmin value for MK-8628 was estimated using dose and steady-state predose concentrations of MK-8628 on Days 29 and 57. The Cmin of MK-8628 after oral administration is presented.
Time frame: Predose on Days 29 and 57
Population: All participants who received MK-8628 and had predose blood samples drawn on Days 29 and 57 for steady state MK-8628 concentration. Participants in the 160 mg dose group were not analyzed for Cmin because they discontinued before Day 29.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| MK-8628 80 mg | Observed Minimum Concentration (Cmin) of MK-8628 | 85.4 μg/Liter | — |
| MK-8628 120 mg | Observed Minimum Concentration (Cmin) of MK-8628 | 54.1 μg/Liter | Standard Deviation 35.4 |
Secondary
Overall Survival (OS)
OS was the time from the start of study treatment to the date of death. Participants were to be censored at their last contact if they were still alive at the cut-off date. OS was calculated for all participants who did not discontinue from the study due to disease progression.
Time frame: Up to 6 Months
Population: All participants who received at least 2 complete cycles (8 weeks) of treatment and had a baseline assessment and 1 on-study MRI or had discontinued early due to disease progression. Since all participants discontinued the study due to disease progression, OS could not be calculated.
Secondary
Progression-free Survival
Progression-free survival was the time from the start of study treatment to the date of clinical or radiographic evidence of progressive disease according to RANO 2010 criteria or death. Progression, as assessed by RANO 2010, was defined as a ≥25% increase in sum of the products of perpendicular diameters of enhancing lesions; any new lesion; or clinical deterioration. PFS was measured as the number of participants who were alive and progression-free for up to 6 months.
Time frame: Up to 6 Months
Population: All participants who received at least 2 complete cycles (8 weeks) of treatment and had a baseline assessment and 1 on-study MRI or had discontinued early due to disease progression.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| MK-8628 80 mg | Progression-free Survival | 0 Participants |
| MK-8628 120 mg | Progression-free Survival | 0 Participants |
| MK-8628 160 mg | Progression-free Survival | 0 Participants |
Secondary
Time to Maximum Concentration (Tmax) of MK-8628
Blood samples were obtained at specified time points for the PK analysis of Tmax of MK-8628. MK-8628 concentrations were analyzed using ultra-performance liquid chromatography coupled with a tandem mass spectrometry and Tmax was calculated using the nonlinear mixed-effects modelling software program Monolix version 4.3.2s. The Tmax of MK-8628 after oral administration is presented.
Time frame: Day 1: Predose and 0.25, 1, 2, 3, 7, and 8 hours postdose
Population: All participants who received MK-8628 and had blood samples drawn for PK analyses.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| MK-8628 80 mg | Time to Maximum Concentration (Tmax) of MK-8628 | 1.7 hours | Standard Deviation 0.498 |
| MK-8628 120 mg | Time to Maximum Concentration (Tmax) of MK-8628 | 2.50 hours | Standard Deviation 0.572 |
| MK-8628 160 mg | Time to Maximum Concentration (Tmax) of MK-8628 | 2.04 hours | — |